Improving Outcomes in Intensively Treated Type 1 and Type 2 Diabetes with Continuous Glucose Monitoring
Recorded on April 17, 2018
Sponsored by Dexcom Inc.
Poor insulin adherence and high A1C values remain prevalent among populations with type 1 or type 2 diabetes who are on intensive insulin therapy. Use of Dexcom continuous glucose monitoring (CGM) technology in these patients is associated with significant A1C reductions, high adherence, and increased time in range. The new Dexcom G6 CGM system can be an effective tool to improve glucose control in patients on multiple-daily injections of insulin or insulin pumps. This presentation will review outcomes data for CGM and describe the G6 system. It will also include discussion on the potential benefits of pharmacy coverage vs medical coverage for CGM systems.
- Renee Taylor, MS, RD, CDE, BC-ADM
Medical Science Liaison, Dexcom Inc.
- Stephanie Redmond, PharmD, CDE
Medication therapy management (MTM) pharmacist and certified diabetes educator at Ridgeview Medical Center in Waconia, Minnesota
This webinar is sponsored, developed and presented by the sponsor. The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.